{
    "nctId": "NCT00337272",
    "briefTitle": "Treating Chronic Insomnia in Breast Cancer Patients",
    "officialTitle": "Phase IV: Treatment of Chronic Insomnia in Patients With Breast Cancer Following Completion of Chemotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Chronic Insomnia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 16,
    "primaryOutcomeMeasure": "Sleep Efficiency",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged 21-60 years old\n* Have a negative serum or urine pregnancy test for women of child-bearing potential\n* Have a three-month or longer history of insomnia\n* Self-report \\< 6.5 hours of total sleep time, in addition to a sleep efficiency of less than 85%, averaged over two weeks of screening\n* A score of less than 60 on the Zung Self-Rating Depression Scale\n* Self-report bedtimes that do not vary by more than two hours on five nights per week\n* Have completed chemotherapy for breast cancer less than two years prior to study drug administration\n* Have completed chemotherapy for breast cancer for at least two months prior to screening visit\n* Patients that are receiving Herceptin are eligible for study enrollment\n* Have completed radiation therapy for breast cancer for at least two months prior to screening visit\n* ECOG (Eastern Cooperative Oncology Group)score of 0-1\n* Be able to read, understand, and provide written informed consent before enrolling in the study\n* Must be willing to comply with all study visits and comply with daily phone calls to the IVRS throughout the study\n* Agree to participate for the entire study period (about two months)\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pregnant or lactating female\n* Self-reports typical consumption of more than five alcoholic beverages on a single day or greater than 14 alcoholic beverages weekly\n* Self-reports use of products containing nicotine of greater than 15 cigarettes daily or cannot avoid products containing nicotine during sleep periods\n* Current use of any of the following medications, and cannot discontinue these medications for the duration of the study: Hypnotic medication, Anti-convulsants, Anxiolytics, Narcotic analgesics, Medications or supplements containing Melatonin, Ketaconazole and Fluconazole\n* Currently taking fluvoxamine, brand name Luvox\n* Have symptoms consistent with the diagnosis of any other sleep disorder other than insomnia (e.g. obstructive sleep apnea, narcolepsy, restless legs syndrome)\n* Currently on night or rotating shift work\n* Self-reports habitual napping of greater than one hour accumulated sleep on 4 or more days per week\n* Has a psychiatric illness that interferes with normal sleep-wake function (e.g. major depression, post-traumatic stress disorder)\n* A score of 60 or greater on the Zung Self-Rating Depression Scale\n* Has current unstable medical disorder, such as symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, or other serious medical condition as determined by the Investigator",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT"
}